posted on 2014-01-03, 00:00authored byJasmin Vassileva, Woo-Young Ahn, Kathleen M. Weber, Jerome R. Busemeyer, Julie C. Stout, Raul Gonzalez, Mardge H. Cohen
OBJECTIVE:
Drug users and HIV-seropositive individuals often show deficits in decision-making; however the nature of these deficits is not well understood. Recent studies have employed computational modeling approaches to disentangle the psychological processes involved in decision-making. Although such approaches have been used successfully with a number of clinical groups including drug users, no study to date has used computational modeling to examine the effects of HIV on decision-making. In this study, we use this approach to investigate the effects of HIV and drug use on decision-making processes in women, who remain a relatively understudied population.
METHOD:
Fifty-seven women enrolled in the Women's Interagency HIV Study (WIHS) were classified into one of four groups based on their HIV status and history of crack cocaine and/or heroin drug use (DU): HIV+/DU+ (n = 14); HIV+/DU- (n = 17); HIV-/DU+ (n = 14); and HIV-/DU- (n = 12). We measured decision-making with the Iowa Gambling Task (IGT) and examined behavioral performance and model parameters derived from the best-fitting computational model of the IGT.
RESULTS:
Although groups showed similar behavioral performance, HIV and DU exhibited differential relationship to model parameters. Specifically, DU was associated with compromised learning/memory and reduced loss aversion, whereas HIV was associated with reduced loss aversion, but was not related to other model parameters.
CONCLUSIONS:
Results reveal that HIV and DU have differential associations with distinct decision-making processes in women. This study contributes to a growing line of literature which shows that different psychological processes may underlie similar behavioral performance in various clinical groups and may be associated with distinct functional outcomes.
Funding
The Chicago WIHS is
funded by the National Institute of Allergy and Infectious Diseases UO1-AI-34993 and co-funded by the National Cancer Institute and the National Institute on
Drug Abuse (NIDA). Jasmin Vassileva was also supported by R01DA021421 from NIDA and the Fogarty International Center and R21DA025417 from NIDA.
Kathleen Weber was additionally supported by the Chicago Developmental Center for AIDS Research P30 AI 082151.